Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 8/20 | 0.47 |
| ▸ | ADORA2A | P29274 | 6/20 | 0.47 |
| ▸ | CDK5 | Q00535 | 2/20 | 0.40 |
| ▸ | CDK5R1 | Q15078 | 2/20 | 0.40 |
| ▸ | CLK1 | P49759 | 5/20 | 0.40 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.37 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.36 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.36 |
| ▸ | SRC | P12931 | 1/20 | 0.36 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.36 |
| ▸ | RXRA | P19793 | 1/20 | 0.35 |
| ▸ | RXRB | P28702 | 1/20 | 0.35 |
| ▸ | RXRG | P48443 | 1/20 | 0.35 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.35 |
| ▸ | AXL | P30530 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5399205 | 0.79 | ADORA1 (0.48) | ADORA1ADORA2ACLK1RPS6KA3 | |
| SCHEMBL5397339 | 0.79 | ADORA1 (0.57) | ADORA1ADORA2A | |
| SCHEMBL16893108 | 0.75 | MAPK1 (0.42) | ADORA1ADORA2ACDK5CDK5R1CLK1 | |
| SCHEMBL5400360 | 0.74 | ADORA1 (0.43) | ADORA1ADORA2ACLK1 | |
| SCHEMBL5397397 | 0.73 | ADORA1 (0.66) | ADORA1ADORA2ACDK5CDK5R1CLK1 | |
| SCHEMBL5401957 | 0.73 | ADORA1 (0.66) | ADORA1ADORA2A | |
| SCHEMBL5396690 | 0.72 | AURKA (0.42) | ADORA1 | |
| SCHEMBL5410470 | 0.72 | ADORA1 (0.65) | ADORA1ADORA2ACDK5CDK5R1CLK1 | |
| Dimethylformamide SCHEMBL27599693 | 0.72 | ADORA1 (0.48) | ADORA1ADORA2ACDK5CDK5R1CLK1 | |
| SCHEMBL6997967 | 0.70 | NOTUM (0.38) | ADORA1ADORA2ACDK5CDK5R1CLK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1363906-B1 | HETEROCYCLIC INHIBITORS OF ERK2 AND USES THEREOF | VERTEX PHARMA (US) | 2015-07-15 | — | — | EP | claimed |
| CN-100534991-C | Heterocyclic inhibitors of ERK 2 and uses thereof | VERTEX PHARMA (US) | 2009-09-02 | — | — | CN | claimed |
| US-6743791-B2 | ANTICANCER AGENTS; ANTIINFLAMMATORY AGENTS | VERTEX PHARMACEUTICALS INCORPORATED | 2004-06-01 | — | — | US | claimed |
| CN-1494541-A | heterocyclic inhibitors of ERK2 and uses thereof | ��̩��˹ҩ��ɷ�����˾ | 2004-05-05 | — | — | CN | claimed |
| EP-1363906-A2 | HETEROCYCLIC INHIBITORS OF ERK2 AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2003-11-26 | — | — | EP | claimed |
| US-20030092714-A1 | Heterocyclic inhibitors of ERK2 and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED | 2003-05-15 | — | — | US | claimed |
| WO-2002064586-A2 | HETEROCYCLIC INHIBITORS OF ERK2 AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2002-08-22 | — | — | WO | claimed |
| EP-1363906-B1 | HETEROCYCLIC INHIBITORS OF ERK2 AND USES THEREOF | VERTEX PHARMA (US) | 2015-07-15 | — | — | EP | disclosed |
| CN-100534991-C | Heterocyclic inhibitors of ERK 2 and uses thereof | VERTEX PHARMA (US) | 2009-09-02 | — | — | CN | disclosed |
| US-20070265263-A1 | Heterocyclic inhibitors of ERK2 and uses thereof | CAO JINGRONG | 2007-11-15 | — | — | US | disclosed |
| US-7253187-B2 | Heterocyclic inhibitors of ERK2 and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-08-07 | — | — | US | disclosed |
| US-20040229875-A1 | Heterocyclic inhibitors of ERK2 and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED | 2004-11-18 | — | — | US | disclosed |
| CN-1494541-A | heterocyclic inhibitors of ERK2 and uses thereof | ��̩��˹ҩ��ɷ�����˾ | 2004-05-05 | — | — | CN | disclosed |
| EP-1363906-A2 | HETEROCYCLIC INHIBITORS OF ERK2 AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2003-11-26 | — | — | EP | disclosed |
| WO-2002064586-A2 | HETEROCYCLIC INHIBITORS OF ERK2 AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2002-08-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070265263-A1 | Heterocyclic inhibitors of ERK2 and uses thereof | MAPK1, MAPK3, MAPKAPK2 | ADORA1 4421/4885ADORA2A 4397/4885CDK5 575/4885 |
| US-20040229875-A1 | Heterocyclic inhibitors of ERK2 and uses thereof | MAPK1, MAPK3, MAP2K2 | ADORA1 4106/4885ADORA2A 4174/4885CDK5 126/4885 |
| US-20030092714-A1 | Heterocyclic inhibitors of ERK2 and uses thereof | MAPK1, MAPK3, MAP2K2 | ADORA1 4106/4885ADORA2A 4174/4885CDK5 126/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.